|

CAR-T Therapy Clinical Trials

6 actively recruiting trials

Pipeline

Phase 1: 4

Top Sponsors

  • Sung-Soo Park2
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
  • Peking University People's Hospital1
  • Guangzhou Women and Children's Medical Center1
  • Beijing GoBroad Hospital1

Indications

  • Cancer4
  • Systemic Lupus Erythematosus (SLE)2
  • Lupus2
  • Relapsed/refractory High Grade B Cell Lymphoma1
  • Systemic Sclerosis (SSc)1

Other6 trials

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
Phase 1
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
Phase 1
Immunotherapy in Lymphoma
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE
Phase 1
To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.